Increased dosage of wild-type KRAS protein drives KRAS-mutant lung tumorigenesis and drug resistance
Tonči Ivanišević, Wout Magits, Yan Ma, Peihua Zhao, Emiel Van Boxel, Benoit Lechat, Edward C. Stites, Greetje Vande Velde, Raj Nayan Sewduth, Anna A. Sablina
This study shows that increased wild-type KRAS protein dosage in KRAS-mutant lung cancer drives tumor growth and drug resistance, with vascular changes mediated by mTOR pathway activation.
bioRxiv · Feb 27, 2024 · PreprintCancer Biology